Amylin Pharmaceuticals, Inc. Release: BYETTA® Provided Greater Glycemic Durability and Overall Glycemic Control than Amaryl® in Patients with Type 2 Diabetes

PHILADELPHIA--(BUSINESS WIRE)--Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced new clinical data from the European Exenatide (EUREXA) study that showed treatment with BYETTA® (exenatide) injection resulted in greater glycemic durability and overall glycemic control than Amaryl®(glimepiride) in patients with type 2 diabetes uncontrolled on metformin alone. These clinical study findings are being presented at the 2012 ADA/The Lancet Symposium today at the 72nd Scientific Sessions of the American Diabetes Association in Philadelphia and will be published in the diabetes-themed issue of The Lancet.

Back to news